SYNOPSIS The efficacy of a selective fusimotor suppressant, the phenothiazine (±)-10-(3-dimethylamino-2-methylpropyl)-2-valeroylphenothiazine, has been assessed in a double-blind crossover trial in eight patients suffering from cerebral spasticity and one patient suffering from spinal spasticity. Dosage was 40 mg daily. Independent clinical and electromyographic methods of assessment were used. The active agent produced a small but significant reduction in spasticity, although this was of clinical value in only a few patients. There were few side-effects. It is recommended that further studies using higher dosages be undertaken.
Neurological thought about spasticity has been dominated by the view that hyperactivity in the fusimotor/muscle spindle system is, if not the major pathophysiological factor, at least a significant contributing factor to the increased tone of spasticity (Rushworth, 1960 (Rushworth, , 1964 Jansen, 1962) . This theory has not met with universal acceptance. Studies of muscle spindle afferent activity in spastic man (Hagbarth et al., 1973) , and in monkeys with chronic lesions involving areas 4 and 6 of the cerebral cortex (Gilman et al., 1974 ) have failed to demonstrate the heightened responsiveness that would result from increased fusimotor drive. An assessment of the efficacy of drugs which block fusimotor function is therefore of interest not only from a therapeutic viewpoint, but also because of the light such an agent may shed on the pathophysiological mechanisms of spasticity.
Phenothiazines have long been known to be capable of abolishing the decerebrate rigidity produced by transection of the mid-brain, a form of rigidity critically dependent on an intact fusimotor system (Henatsch and Ingvar, 1956 ). Recently phenothiazines have been shown to reduce the firing rate of both static and dynamic fusimotor neurones in doses comparable with those which abolish decerebrate rigidity (Max- (Accepted 30 November 1974.) 469 well and Rhodes, 1970; Sumpter, 1972, 1974) and it has been suggested that the site of action is the brain-stem reticular formation, on a bulbospinal noradrenergic pathway Sumpter, 1972, 1974) . The clinical usefulness of some phenothiazines, such as chlorpromazine, has been limited by soporific effects, but with other derivatives it has proved possible to separate sedative activity from the depressant action on the fusimotor system (Keary and Maxwell, 1967) . One such derivative, dimethothiazine, has demonstrated some beneficial activity in spastic man (Matthews et al., 1972) , and in childhood cerebral palsy (Griffiths and Bowie, 1973) , but phototoxicity, and other problems limit its usefulness. A more recent derivative, (± )-10-(3-dimethylamino-2-methylpropyl)-2-valeroylphenothiazine; also known as M & B 18706, has proved to be a more potent and potentially less toxic agent Sumpter, 1972, 1974; . Like other phenothiazines, this drug appears to have selective action on the fusimotor system, an action that can fully explain its effects on decerebrate rigidity . Unlike baclofen, an agent of established efficacy in spinal spasticity, it has no significant effect on standard segmental spinal reflexes . This phenothiazine derivative has been subjected to double-blind clinical evaluation in a small group of patients with predominantly cerebral spasticity, the clinical findings being complemented by an objective assessment based on the electromyographic analysis described by Jones et al. (1970) , and Ashby et al. (1972) . The encouraging results of the trial suggest that further evaluation is warranted.
METHODS
Nine patients were studied. Spasticity resulted from cerebral lesions in eight patients, five of whom suffered residual spastic hemiparesis after thrombotic or haemorrhagic strokes, and two of whom were hemiparetic after trauma. The eighth patient was hemiparetic due to an undiagnosed cortical lesion, and the remaining patient was quadriplegic due to a Klippel-Feil anomaly which had resulted in cervical spine cord compression. Of (0), through slight (1), moderate (2), and marked resistance (3) to complete rigidity of the limb. Tendon reflexes were recorded as 0 (absent), 1 (reduced), 2 (normal), 3 (increased), and 4 (markedly increased). The duration of muscle clonus was recorded in seconds, longer than 30 seconds being regarded as maximal.
The electromyographic (EMG) assessment was performed by two of the authors on the 13th or 14th day of each treatment period. This assessment was carried out completely independently of the clinical evaluation, there being no collusion between authors until the completion of the study. Full details of the electromyographic methods have been given in previous trials (Jones et al., 1970; Ashby et al., 1972) . The reflex EMG responses of the quadriceps and hamstrings muscle groups were recorded by surface electrodes in standardized positions while the muscles were stretched passively at different rates by manual movements of the knee. Direct EMG, integrated EMG, knee joint position, and velocity of stretch were recorded for each muscle group.
For each patient the dynamic stretch reflex was then represented by a scatter diagram produced by plotting the velocity of the stretching movement against the amplitude of the resulting integrated EMG response. Linear regression analysis was performed for those movements which produced EMG, the correlation coefficient of the regression line being considered significant only if it exceeded 0.6. Nonsignificant data were excluded from further calculations. The tone on active therapy was greater than that on placebo therapy in seven of the nine patients as assessed in the upper limb, and in five of eight patients in the lower limb, the ninth patient having had no evidence of increased tone in the lower limbs in pre-trial assessments (Fig. 1) . In two patients (nos 2 and 5), in whom the placebo response appeared greater than that on M & B 18706, spasticity was mild, the changes were small, and the active agent had been administered in the first treatment period. The slight improvement achieved by the end of this treatment period appeared to be quite well maintained during the subsequent placebo phase, there being no intervening period during which no tablets were administered. Random allocation of medication resulted in only three patients commencing active therapy in the first treatment period. The third patient, who had more severe spasticity, also noticed some continuation of improvement into the subsequent placebo phase (greater ease of walking due to lessened 'stiffness'), but to objective examination muscle tone reverted to the pre-trial level. Thus, compared with pre-trial assessments, spasticity decreased during the trial in eight of the nine patients, each to a variable extent, although these benefits could not be confidently attributed to the active agent alone.
During treatment with the active agent, power ofintrinsic muscles ofthe hand (finger adductors) improved in three patients, two of whom had no obvious active finger adduction before treatment. This unexpected finding presumably resulted from greater ease of movement because of a reduction in spastic stiffness. There was no uniform or sustained change in tendon reflexes or clonus. Such a change might be expected with an agent which acts on the fusimotor system; the absence of such an effect could result from difficulties of accurate clinical assessment.
Treatment with M & B 18706 resulted in functional improvement in four patients (two slight, one moderate, one marked). Three patients noted no functional difference, while two patients (numbers 6 and 8) felt they were worse on the active agent due to side-effects, and to greater clumsiness resulting from a definite reduction in spasticity. After completion of the trial, three of the five patients who failed to gain functional benefit have since noticed a slight deterioration, and have expressed a preference to remain on the active agent.
ELECTROMYOGRAPHIC ASSESSMENT Inspection of the scatter diagrams of integrated EMG plotted against velocity of the stretching movement showed that for each patient a smaller reflex EMG response was produced during active treatment than during placebo treatment. The differences were small, and not of the same degree in the hamstrings and the quadriceps muscles (Fig. 2) . In three subjects no appreciable change in the EMG velocity relationship resulted from treatment in one muscle group, but active treatment resulted in a slight reduction in the EMG response in the other muscle group.
The remaining six subjects had a minor improvement in one muscle group accompanied by moderate to marked changes in the other.
Statistical analysis was performed for the data from eight patients, that from the ninth being rejected as unreliable because the patient was tense and unable to relax during the testing and correlation coefficients were low. Data on the quadriceps muscle of a second patient were not significantly linear (low correlation coefficients), and the data on the hamstrings of a third patient were unreliable due to technical problems. Although excluded from further analysis, inspection of these data suggested that active treatment was beneficial in each case. Thus in the eight subjects further analysis was performed for the quadriceps in seven and for the hamstrings in seven. The correlation coefficients for these regression equations are detailed in Table 1 . The increases in threshold velocity produced by the active agent are shown in Table 2 . When each muscle group was considered separately the increase was not statistically significant, possibly due to the small sample sizes. On pooling the data from the two muscle groups to provide a larger sample, the mean increase in threshold velocity of 39.3°/s was quite significant (P < 0.02).
The decrease in EMG activity produced at 300°/s resulting from active treatment (Table 3) was significant in each muscle group when considered separately, and was highly significant (P <0.005) when the data from the two muscle groups were pooled. Although the changes produced by treatment were small, they were largely in the same direction, and consequently they achieved statistical significance, a significance that has resulted not from the magnitude but from the consistency of the change. While it may be concluded that a reduction in spasticity has been demonstrated, it cannot be concluded that worthwhile clinical improvement accompanied this reduction. Certainly the magnitude of the electromyographic change was such that in at least two patients significant clinical improvement might be expected. This is particularly so in the sole patient with spinal spasticity. During placebo treatment the reflex activity of this patient's hamstrings was so intense that stretching movements produced prolonged EMG activity which subsided very slowly after cessation of movement. This 'static' stretch reflex response was virtually abolished by the active treatment. 
